Serimmune, Inc.

9:45 AM - 10:00 AM (EDT), Tuesday, October 22, 2019 ・ 2nd Floor
Serimmune is an immune intelligence company focused on providing a holistic view of adaptive immune response and identifying critical immune factors in disease and health. Central to our efforts is the Serum Epitope Repertoire Analysis (SERA) platform that combines bacterial display peptide libraries, next generation sequencing, machine learning and custom bioinformatics to reveal the many diverse antigens stimulating the adaptive immune system. Serimmune leverages these data to build our human immunity map, a growing database that can be interrogated to characterize immunity and immune responses, enabling development of next generation diagnostics, vaccines and therapeutics. The company is actively pursuing commercial partnerships around the SERA platform and has a number of ongoing collaborations with government, academic and commercial organizations. The company was founded in 2014 and is backed by investors including Illumina Ventures, LabCorp, and Merck.
Company Type:
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
SERA Tick Born Disease Panel
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Chief Executive Officer
Serimmune, Inc.